Key result
Low ion channel risk scores predict higher survival and better immunotherapy response in lung adenocarcinoma.
Why the study?
Expression and functional dysregulation of ion channel genes are correlated with unfavorable prognosis in lung adenocarcinoma, motivating development of an ion channel-based prognostic model.
Does an ion channel-based risk model predict prognosis and treatment response in patients with lung adenocarcinoma?
Cohort
Does an ion channel-based risk model predict prognosis and treatment response in patients with lung adenocarcinoma?
An ion channel-based risk model can independently predict survival, immune infiltration, and drug sensitivity in patients with lung adenocarcinoma.
Answers are grounded in this paper and cite their sources.
May support ion channel stratification in lung adenocarcinoma; hypothesis-generating pending prospective validation.
Expression and functional dysregulation of ion channel genes are correlated with an unfavorable prognosis in lung adenocarcinoma (LUAD). Ion channel signature for predicting the prognosis of individuals with LUAD. 94 ion channel-related differentially expressed genes in LUAD were identified from TCGA-LUAD, and ion channel-based LUAD risk model was established and validated using the GEO cohort. Survival analysis outcomes demonstrated that low-risk LUAD patients were accompanied with higher survival rates. Cox analysis manifested that LUAD prognostic risk score was an independent prognosticactor. We plotted a nomogram with clinical utility based on LUAD risk score and clinical factors. Differentially expressed genes in LUAD patients of different risk groups were enriched in biological functions and signaling pathways related to ion channels, cancer transcription dysregulation, and immunity. Immune infiltration results suggested that LUAD patients with low risk scores exhibited better immune cell infiltration and function. Prediction results of immunotherapy response showed that LUAD patients with low risk scores had a higher chance of benefiting from immunotherapy. The drug prediction results showed that individuals with LUAD in the low-risk group were more sensitive to paclitaxel, BI 2536, pyrimethamine, and VX-680, while individuals with LUAD in the high-risk group to erlotinib, sorafenib, panitumumab, PHA-665752, and roscovitine. In summary, ion channel-related genes can provide valuable information for prognosis assessment and drug treatment of LUAD patients.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2024) conducted a cohort in Lung adenocarcinoma (LUAD). Ion channel-based LUAD risk score vs. High risk score was evaluated on Survival rates. An ion channel-based risk score demonstrated that low-risk lung adenocarcinoma patients had higher survival rates and better predicted immunotherapy response compared to high-risk patients.
Synapse has enriched 10 related papers. Consider them for comparative context: